OBJECTIVE： To investigate the role of clinical pharmacists on drug therapy for acute exacerbations of chronic obstructive pulmonary disease（AECOPD）patients with benign prostatic hyperplasia （BPH）. METHODS： Clinical pharmacists participated in drug therapy for a AECOPD patient with BPH. According to clinical guideline and relevant literatures， based on the history of disease， the characteristics of bronchodilators and the symptoms of acute urinary retention， it was suggested to stop taking Ipratropium bromide solution for inhalation but receive Finasteride capsules 5 mg， po， qd， to reduce prostate volume and improve obstruction+Terazosin hydrochloride tablets 2 mg， po， qd， to relax urethral smooth muscle； the occurrence of ADR was monitored closely. Salmeterol xinafoate and fluticasone propionate powder for inhalation was suggested and medication guidance for patients after discharge was given by clinical pharmacists. RESULTS： Physicians adopted some suggestions of clinical pharmacists. The patient was stable and had no dysuria. The patient was allowed to leave the hospital with drugs. CONCLUSIONS： Rational use of bronchodilators is directly related to the remission of clinical symptoms and prognosis in AECOPD patients. In view of patient’s disease history， drug characteristics and clinical symptoms， clinical pharmacists point to possible risks of anticholinergics use， and assist physicians to formulate and adjust therapy plan so as to guarantee the safety and effectiveness of drug use.